Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Kura Oncology (NASDAQ:KURA) Sees Strong Trading Volume theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Kura Oncology, Inc. shares are trading higher Tuesday after the company reported preliminary clinical data from the first 20 patients its Komet-007 Phase 1 dose-escalation trial. Kura reported that all newly diagnosed patients treated with ziftomenib and 7+3 achieved a complete remission (CR) with full count recovery, for a CR rate of 100% (5/5), including four patients with NPM1-m acute myeloid leukemia (AML) and one patient with KMT2A-r AML.
Shares of United Parcel Service, Inc. (NYSE: UPS) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter sales results and issued FY24 sales